MedPath

effect of administration of intrathecal Dexmedetomidine on the Spinal Cord Mori

Phase 3
Recruiting
Conditions
umbar disc herniation.
Thoracic, thoracolumbar, and lumbosacral intervertebral disc disorders
Registration Number
IRCT20200127046282N1
Lead Sponsor
Vice chancellor for research, Shahid Beheshti University of Medical Sciences , Loghman Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
40
Inclusion Criteria

No history of taking anti-inflammatory drugs two weeks before surgery
Lack of AIDS and immunosuppressive diseases

Exclusion Criteria

GCS reduction for a reason other than stroke
Change in the type of surgery according to the surgeon's opinion
History of systemic diseases such as diabetes mellitus, renal failure and chronic pulmonary heart disease

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The level of Bax / Bcl-2¬ apoptotic factor in cerebrospinal fluid in dexmedetomidine and placebo group. Timepoint: After surgery and at the end of surgery. Method of measurement: Study of cerebrospinal fluid in dexmedetomidine and placebo group by ELISA.;Numering Rating Scale (NRS) Pain score in dexmedetomidine and placebo group. Timepoint: Before anesthesia and in recovery. Method of measurement: NRS scoring system.;The level of caspase-3 apoptotic factor in cerebrospinal fluid in dexmedetomidine and placebo group. Timepoint: After surgery and at the end of surgery. Method of measurement: Study of cerebrospinal fluid in dexmedetomidine and placebo group by ELISA.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath